Drug Profile
Research programme: polymer-formulated camptothecin - Avantogen Oncology
Alternative Names: BIO 119; INOC010Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Avantogen Oncology
- Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
- 30 May 2006 Innovate Oncology has been acquired by Avantogen
- 13 May 2005 Preclinical trials in Cancer in USA (unspecified route)